Sales for the quarter of $3.03M, up 42.5% from the prior year period
o Growth reflects Cardiocel®’s increasing global availability and traction
o CardioCel® now in 110 centres globally
Cash balance at 30 September 2015 of $16.7M
Initiated a key aortic heart valve reconstruction post-market clinical study using CardioCel® at leading global heart centres
HSV-2 Phase II nearing completion, with interim results due at end of this calendar year
Manufacturing of the HPV therapeutic vaccine completed in preparation for Ian Frazer’s next HPV product heading into the clinic
Admedus Vaccines rebrands as Admedus Immunotherapies
Ann: Appendix 4C - quarterly, page-3
-
- There are more pages in this discussion • 154 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.00 |
Change
0.150(1.01%) |
Mkt cap ! $317.0M | |||
| Open | High | Low | Value | Volume |
| $15.00 | $15.15 | $14.30 | $210.2K | 14.26K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $14.60 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.00 | 5153 | 3 |
View Market Depth
| Last trade - 16.10pm 14/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |